newsfilter
← Earnings
Earnings Releases·

Acumen Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $25.4 million for Q3 2026 from $26.5 million in the prior year period, with R&D expenses declining to $21.1 million from $22.0 million, driven by reduced ALTITUDE-AD trial costs offset by increased EBD program spending.
  • Cash and marketable securities decreased to $78.6 million as of September 30, 2026, from $110.2 million in June 2026, though proceeds from a $35.4 million private placement and $30.5 million in financing activities during the nine months ended September 30, 2026, supported liquidity.
  • The company expects to report topline results for the ALTITUDE-AD Phase 2 study in November 2026 and targets an IND filing for its EBD lead candidate in mid-2027, with current cash resources projected to fund operations into early 2027.
  • Capital structure changes included a $5.0 million debt repayment and an increase in short-term debt to $20.4 million (from $8.8 million), while total assets declined to $85.6 million and stockholders' equity fell to $34.6 million compared to year-end 2025 levels.
Company
ACUMEN PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology